The honest framing
The first thing to clear up: "Ozempic vs Mounjaro" is the question patients bring in from social media. In India in 2026, the more accurate clinical question is Wegovy vs Mounjaro — because Ozempic in India is licensed only for type 2 diabetes (max 1 mg weekly) and Wegovy is the obesity-indicated semaglutide that reaches the 2.4 mg dose used in the major weight-loss trials. Ozempic is the same molecule at lower doses for a different indication.
So the real comparison is: semaglutide 2.4 mg (Wegovy) vs tirzepatide 5–15 mg (Mounjaro). The rest of this blog uses "Ozempic" loosely to mean "the semaglutide molecule" because that's the term most patients search for. For clinical precision, see our complete guides on semaglutide and tirzepatide.
The executive answer
- Tirzepatide (Mounjaro) delivers meaningfully greater absolute weight loss than semaglutide in the only direct head-to-head obesity trial published to date (SURMOUNT-5, NEJM 2025), and superior HbA1c reduction in T2D (SURPASS-2, NEJM 2021).
- Semaglutide (Wegovy/Ozempic) has the deeper cardiovascular outcomes record — SELECT and SUSTAIN-6 are large multi-year hard-endpoint trials that tirzepatide doesn't yet match.
- Both are excellent drugs. Choice depends on your goals, tolerability, and individual response.
2-minute eligibility test. Free. We'll see if Kaivo is the right fit for you.
SURMOUNT-5 — the only direct head-to-head obesity trial
SURMOUNT-5 (Aronne et al., N Engl J Med 2025;393(1):26–36; NCT05822830) is the first and only completed randomised head-to-head obesity trial of tirzepatide vs semaglutide.
Design: Phase 3b, multicentre, open-label, 1:1 randomised, 72 weeks. 751 adults with obesity or overweight plus at least one weight-related complication, without diabetes. Maximum tolerated tirzepatide (10 or 15 mg) vs maximum tolerated semaglutide (1.7 or 2.4 mg). 89.3% of the tirzepatide arm reached 15 mg; 92.8% of the semaglutide arm reached 2.4 mg — so this is genuinely a maximum-dose comparison.
Primary endpoint (week 72):
- Tirzepatide: −20.2% body weight
- Semaglutide: −13.7% body weight
- Treatment difference: −6.5 percentage points (~47% greater relative weight loss with tirzepatide)
- p < 0.001; all five key secondary endpoints also favoured tirzepatide
Waist circumference: −18.4 cm (tirzepatide) vs −13.0 cm (semaglutide). Categorical loss: roughly one-third of the tirzepatide group lost ≥25% of body weight, versus roughly one-eighth of the semaglutide group.
Tolerability was surprising:
- Serious adverse events: 4.8% (tirzepatide) vs 3.5% (semaglutide) — numerically higher with tirzepatide, not statistically significant
- Any-cause discontinuation: 6.1% (tirzepatide) vs 8.0% (semaglutide)
- GI-related discontinuation: 2.7% (tirzepatide) vs 5.6% (semaglutide) — counter-intuitively, semaglutide caused more discontinuations despite tirzepatide producing larger weight loss
- Zero deaths in either arm
Important limitation: open-label design (placebo would have been clearly distinguishable); population was predominantly white North American; no South Asian subgroup analysis has been published. We're extrapolating Indian outcomes from Western trial data.
SURPASS-2 — the head-to-head in type 2 diabetes
SURPASS-2 (Frías et al., NEJM 2021;385:503–515). 40 weeks, 1,879 adults with T2D on metformin. Mean baseline HbA1c 8.28%, weight 93.7 kg.
| Arm | ΔHbA1c | Weight loss | ≥15% loss |
|---|---|---|---|
| Tirzepatide 5 mg | −2.01% | −7.6 kg | 15% |
| Tirzepatide 10 mg | −2.24% | −9.3 kg | 28% |
| Tirzepatide 15 mg | −2.30% | −11.2 kg | 40% |
| Semaglutide 1 mg | −1.86% | −5.7 kg | 9% |
92% on tirzepatide 15 mg reached HbA1c <7%; 51% reached <5.7% (normal-range glycaemia).
Critical caveat: SURPASS-2 used semaglutide 1 mg — the highest T2D-approved dose. Wegovy reaches 2.4 mg. So SURPASS-2 is not a fair fight at maximum semaglutide. SURMOUNT-5 is the fair fight, and tirzepatide still wins.
Mechanism — why tirzepatide may go further
Semaglutide is a single-target GLP-1 receptor agonist. It mimics one gut hormone — glucagon-like peptide-1. GLP-1 tells the brain "I'm full," slows stomach emptying, and pushes the pancreas to release insulin only when blood sugar is high.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It mimics two gut hormones simultaneously — GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). GIP receptors sit on fat cells and in specific brain regions that don't fully overlap with GLP-1 receptors. In preclinical work, adding GIP agonism: (a) makes fat cells healthier and improves their ability to store fat subcutaneously rather than viscerally; (b) blunts the nausea/aversion signal of GLP-1 in the brainstem, allowing higher effective dosing; (c) improves insulin sensitivity independent of weight loss.
For an Indian patient with a "thin-fat" phenotype, the GIP component is theoretically attractive because GIP signalling targets adipose tissue dysfunction and visceral fat. But no Indian RCT has confirmed this in practice yet. Treat it as biologically plausible, not proven.
Side effects — head-to-head
Both drugs share the same major side-effect class (gastrointestinal) and the same boxed warning (medullary thyroid carcinoma — based on rodent studies, no convincing human signal). For the Indian-relevant thyroid nuance, see our thyroid and weight guide.
The empirical pattern from SURMOUNT-5: at maximum dose, tirzepatide is the better-tolerated drug in head-to-head comparison, despite producing deeper weight loss. This is the opposite of what most patients assume.
- Nausea: ~44% at semaglutide 2.4 mg vs 25–33% across tirzepatide doses
- Diarrhoea: 30% vs 19–23%
- Vomiting: 24% vs 8–13%
- GI-specific discontinuation: 4.3–5.6% vs 1.0–2.7%
Indian dietary considerations
No Indian RCT data exists for either drug, so this section is grounded in clinical reasoning rather than published evidence.
- High-fibre dal-roti diets combined with GLP-1/GIP gastric-emptying delay can worsen bloating and reflux. Space meals, reduce raw salad volume early, prefer cooked vegetables during titration.
- Vegetarian protein gap: appetite suppression of 700–1,000 kcal/day risks driving protein intake below 0.8 g/kg/day in lacto-vegetarians, accelerating sarcopenia in already low-muscle-mass Indians. Target ≥1.2 g/kg/day during active weight loss.
- Pre-existing IBS or gastroparesis-like symptoms — common in Indian women with PCOS — require slower titration with longer dwell at starter doses.
- Ramadan, Karwa Chauth, Navratri fasts: mealtime injection timing and hydration need protocolised counselling. Not in any pivotal trial.
A decision framework
Archetype A — BMI 27–32, no comorbidities, cosmetic/lifestyle weight loss
Likely fit: Wegovy (semaglutide 2.4 mg). STEP-1 demonstrates ~15% weight loss, which exceeds the typical patient's goal. The 6.5-percentage-point advantage of tirzepatide is real but not necessary if you're targeting modest loss. Wegovy maintenance is also typically cheaper monthly than Mounjaro 15 mg. Reserve tirzepatide for non-responders at month 6.
Archetype B — PCOS plus insulin resistance, BMI 28–33
Likely fit: lean Wegovy. The best-quality (though still small) PCOS RCT evidence is for semaglutide — Jensterle et al. showed 11.5 kg loss at 6 months with semaglutide 0.5 mg in obese PCOS women, with 80% restoring menstrual regularity. Tirzepatide is biologically attractive (better on insulin sensitivity) but lacks PCOS RCTs. Consider tirzepatide if (a) frank prediabetes or HbA1c 5.9–6.4%, or (b) inadequate response to semaglutide at 6 months. Continue metformin alongside either. See our PCOS guide for the broader workup.
Archetype C — Type 2 diabetes, HbA1c >7.5%, BMI ≥30
Likely fit: Mounjaro. SURPASS-2 demonstrates HbA1c reductions of 2.0–2.3% with tirzepatide vs 1.86% with semaglutide 1 mg; weight loss is also superior. 92% of tirzepatide 15 mg patients reach HbA1c <7%. Mounjaro is labelled for both T2D and obesity in India, simplifying prescribing. Consider Ozempic 1 mg as an alternative for patients who cannot tolerate tirzepatide or have HbA1c <8.5%. See our diabetes guide.
Can you switch between them?
Yes. Standard practice: stop semaglutide, wait a week, start tirzepatide at 2.5 mg, retitrate from the bottom. There is no validated dose-equivalence chart between the two drugs. Real-world cross-over data is accumulating but no RCT-grade switching protocol exists.
You cannot take both at the same time. Overlapping mechanism, additive GI toxicity, no efficacy benefit demonstrated, and pancreatitis risk compounds.
The honest summary
If you primarily want the deepest weight loss your body can produce, the evidence currently favours tirzepatide. If you have established cardiovascular disease or chronic kidney disease and want a drug with a long, large hard-endpoint dataset, semaglutide has more years of outcomes data. Most patients do well on either.
The variables that should drive your individual choice are your specific HbA1c, BMI, comorbidities, and what your body tolerates — not what a celebrity uses on Instagram. That's what your AIIMS-trained Kaivo physician spends the consult sorting out.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989–1002.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
- Jensterle M, Ferjan S, Vovk A, et al. Semaglutide treatment of obese PCOS patients unresponsive to lifestyle programs. J Clin Med. 2023;12(18):5921.